Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCE-01
- Development stage
- Preclinical
- Lead developer
- MetaFines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NCE-01 is a preclinical-stage small molecule candidate developed by MetaFines, a biotechnology company focused on metabolic and mitochondrial health. The drug is being investigated for the treatment of muscle-wasting conditions, including sarcopenia (age-related muscle loss) and various forms of muscular dystrophy. NCE-01 is designed to improve muscle function and mass by enhancing mitochondrial biogenesis and metabolic efficiency. By addressing mitochondrial dysfunction, which is a hallmark of muscle degeneration, the compound aims to restore muscle strength and physical performance in patients with degenerative muscle diseases.
Beyond the preview
Go deeper on NCE-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCE-01.